Spyre Therapeutics, Inc. (SYRE)

SEC filing

Spyre Therapeutics, Inc.

SYRE · CIK 1636282

4 · Sep 3, 2026 · Chief Financial Officer Burrows Scott L sold 25.73K shares at $88.75/share ($2.3M); exercised options for 15K shares

Chief Financial Officer Burrows Scott L sold 25.73K shares at $88.75/share ($2.3M); exercised options for 15K shares

Could not load the primary document from EDGAR (SEC rate limit, timeout, or temporary upstream error). Refresh in a minute, or use View on SEC.gov.